New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
09:11 EDTBKS, CVRR, PXD, SQBG, OMI, MDCI, GLNG, AERI, NSPH, BMY, GIS, MON, IMSOn The Fly: Pre-market Movers
HIGHER: Barnes & Noble (BKS), up 7.7% after board authorizes management to separate Retail, Nook Media units... Monsanto (MON), up 5% after reporting better than expected Q3 results, raising its full year EPS outlook to the upper end of its previous guidance range and announcing a new $10B share repurchase authorization... IMS Health (IMS), up 7.7% after acquiring certain Cegedim businesses for $520M... Nanosphere (NSPH), up 16.2% after receiving 510(k) clearance for bacterial portion of Verigene EP test... Aerie Pharmaceuticals (AERI), up 37% after its trial of Roclatan achieved its primary efficacy endpoint... Medical Action (MDCI), up 94% after Owens & Minor (OMI) acquires the company for $13.80 per share in cash... Sequential Brands (SQBG), up 15% after acquiring Galaxy Brand for $100M cash, 13.75M shares... Pioneer Natural (PXD), up 2.3% after media reports that the company got U.S. permission to ship a type of light oil known as condensate... Bristol-Myers Squibb (BMY), up 2% after a Phase 3 study of nivolumab was halted early due to superior data. LOWER: General Mills (GIS), down 3.7% after Q4 earnings fall below analyst's consensus... Lindsay Corp. (LNN), down 5% after earnings miss, saying Iraq contract now more difficult to complete... Golar LNG (GLNG), down 2% after 11M share offering priced at $54 per share... CVR Refining (CVRR), down 7% after 6M share secondary offering of common units price at $26.07.
News For BKS;MON;GIS;BMY;NSPH;AERI;GLNG;MDCI;OMI;SQBG;PXD;CVRR;IMS From The Last 14 Days
Check below for free stories on BKS;MON;GIS;BMY;NSPH;AERI;GLNG;MDCI;OMI;SQBG;PXD;CVRR;IMS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 27, 2014
06:42 EDTBMYBristol-Myers initiated with a Hold at Deutsche Bank
Target $52.
06:10 EDTPXDPioneer Natural downgraded to Hold from Buy at Canaccord
Subscribe for More Information
05:44 EDTBMYBristol-Myers Daklinza approved by EC
Bristol-Myers announced that the European Commission, or EC, has approved Daklinza for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus, or HCV, infection in adults. Daklinza, when used in combination with sofosbuvir, is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials, including patients with advanced liver disease, genotype 3 and those who have previously failed treatment with protease inhibitors. Daklinza is the first NS5A complex inhibitor approved in the European Union and will be available for use in combination with other medicinal products, providing a shorter treatment duration compared to 48 weeks of treatment with interferon- and ribavirin-based regimens. The approval allows for the marketing of Daklinza in all 28 Member States of the EU. The marketing authorization for Daklinza follows an accelerated assessment by the Committee for Medicinal Products for Human Use, a designation that is granted to new medicines of major public health interest.
August 26, 2014
09:48 EDTGLNGGolar LNG says recent weeks show moderate improvement in chartering demand
Golar LNG said, "Although recent weeks have shown a moderate improvement in chartering demand, the Board believes that this is primarily linked to a temporary market condition related to the current contango in the LNG pricing curve going out into the winter of 2014/15. Supply demand fundamentals remain challenging and therefore investors should anticipate operating results for the balance of the year to be generally in line with the first half of 2014. In recognition of the current improved utilisation of the spot vessels, all of which are currently employed, operating results for the third quarter can however be expected to show some minor improvement over the second quarter...The company fulfilled its commitment to complete and obtain funding for the company's maiden FLNG vessel as of the end of the second quarter 2014. The proceeds from the offering put the company on a solid footing to maintain a fast track schedule for yard delivery of the first FLNG vessel in the first quarter of 2017. The company has made positive progress on securing agreements for the deployment of the vessel to coincide with the delivery timing from the yard."
09:45 EDTGLNGGolar LNG reports Q2 operating revenue $21.08M, consensus $20.36M
Subscribe for More Information
09:30 EDTMONGlobal Hunter Securities to hold meetings at farm show
Global Hunter Events at Farm Progress Show in Boone, Iowa on August 26-27.
09:25 EDTMONFarm Progress Companies to hold a show
Subscribe for More Information
August 25, 2014
15:18 EDTGLNGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Best Buy (BBY), consensus 31c; Golar LNG (GLNG), consensus (7c); DSW (DSW), consensus 32c; Tech Data (TECD), consensus 77c; Sanderson Farms (SAFM), consensus $3.82; Movado (MOV), consensus 54c; Trina Solar (TSL), consensus 14c.
August 22, 2014
17:04 EDTSQBGCarlyle Group reports 16.1% stake in Sequential Brands
Subscribe for More Information
12:39 EDTBMYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
08:15 EDTMONMonsanto can execute another reinvention, says Citigroup
Citigroup believes Monsanto is reinventing itself like it did when Roundup went off patent in the late 1990's by using the cash flow from the seeds business to get into new growth areas. Citi thinks management can execute the transition but admits the stock may be range-bound over the near-term. The firm keeps a Buy rating on Monsanto with a $146 price target.
08:02 EDTGLNGGolar LNG price target raised to $78-$90 from $55-$60 at Wells Fargo
Subscribe for More Information
August 21, 2014
13:32 EDTBMYBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
August 20, 2014
12:07 EDTMONMonsanto expects to at least double year ongoing EPS by end of FY19
Subscribe for More Information
12:03 EDTMONMonsanto says on track to deliver upper end of FY14 outlook
Subscribe for More Information
09:32 EDTBKSSamsung, Barnes & Noble announce new Samsung Galaxy Tab 4 NOOK
Subscribe for More Information
08:03 EDTBMYBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
08:02 EDTBMYBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 19, 2014
15:48 EDTBKSCNET to hold a live blog
CNET holds a live blog of the unveiling of Samsung and Barnes & Noble's Nook tablet in New York on August 20 at 9:30 am. Webcast Link
13:40 EDTBKSBarnes & Noble to start selling new Samsung tablet tomorrow, Digital Reader says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use